Home > Publications database > Dendritic cells in multiple myeloma: from immune evasion to therapeutic potential. > print

001     300752
005     20250503112950.0
024 7 _ |a 10.3389/fimmu.2025.1575509
|2 doi
024 7 _ |a pmid:40313957
|2 pmid
024 7 _ |a pmc:PMC12043573
|2 pmc
037 _ _ |a DKFZ-2025-00912
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Jordan, Melanie
|0 P:(DE-He78)75b4f74b753faeb8e48695b4710b3612
|b 0
|e First author
|u dkfz
245 _ _ |a Dendritic cells in multiple myeloma: from immune evasion to therapeutic potential.
260 _ _ |a Lausanne
|c 2025
|b Frontiers Media
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1746194743_32
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:D431#LA:D431#
520 _ _ |a Multiple myeloma (MM) is a type of hematologic cancer characterized by the uncontrolled clonal expansion of plasma cells in the bone marrow (BM). This leads to significant dysfunction and suppression of the immune system in affected patients. Myeloma cells employ sophisticated strategies to manipulate immune and non-immune cells, evading immune surveillance and enhancing their survival. One key factor in this evasion is the disruption of dendritic cell (DC)-mediated immune mechanisms. Extensive evidence indicates that in the presence of myeloma cells, DC numbers are notably reduced, and their phenotype and function are altered, impairing their ability to present antigens and activate robust T-cell responses effectively. Despite rapid advances in MM treatment, with promising strategies such as DC-based vaccines being already achieved, DC dysfunction remains a substantial hurdle, associated with or contributing to poor therapeutic outcomes, disease relapse, and MM's persistence as an incurable disease. To address these challenges, it is essential to understand the intricate mechanisms through which myeloma cells transform DCs into their 'accomplices,' undermining immune responses. This review comprehensively summarizes the current understanding of the role of DCs in MM. Additionally, it evaluates the potential of DCs in anti-MM immunotherapy, discussing persistent challenges and highlighting emerging perspectives that may lead to promising breakthroughs for improved patient outcomes.
536 _ _ |a 314 - Immunologie und Krebs (POF4-314)
|0 G:(DE-HGF)POF4-314
|c POF4-314
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a DC vaccine therapy
|2 Other
650 _ 7 |a dendritic cells
|2 Other
650 _ 7 |a immune evasion
|2 Other
650 _ 7 |a multiple myeloma
|2 Other
650 _ 7 |a tumor microenvironment
|2 Other
700 1 _ |a Morschl, Johannes
|0 P:(DE-He78)da4a4bbbdbe57436d712dd4130f6cd4d
|b 1
|u dkfz
700 1 _ |a Autenrieth, Stella
|0 P:(DE-He78)d3dbba28fe1239effd15962787cbc363
|b 2
|e Last author
|u dkfz
773 _ _ |a 10.3389/fimmu.2025.1575509
|g Vol. 16, p. 1575509
|0 PERI:(DE-600)2606827-8
|p 1575509
|t Frontiers in immunology
|v 16
|y 2025
|x 1664-3224
909 C O |o oai:inrepo02.dkfz.de:300752
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)75b4f74b753faeb8e48695b4710b3612
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)da4a4bbbdbe57436d712dd4130f6cd4d
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)d3dbba28fe1239effd15962787cbc363
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-314
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Immunologie und Krebs
|x 0
914 1 _ |y 2025
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b FRONT IMMUNOL : 2022
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-12-29T15:23:07Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-12-29T15:23:07Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2023-12-29T15:23:07Z
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2023-12-29T15:23:07Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-28
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-28
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b FRONT IMMUNOL : 2022
|d 2024-12-28
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-28
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-28
920 2 _ |0 I:(DE-He78)D431-20160331
|k D431
|l Dentritische Zellen bei Infektionen und Krebs
|x 0
920 1 _ |0 I:(DE-He78)D431-20160331
|k D431
|l Dentritische Zellen bei Infektionen und Krebs
|x 0
920 0 _ |0 I:(DE-He78)D431-20160331
|k D431
|l Dentritische Zellen bei Infektionen und Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)D431-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21